The Society is pleased to report that its evidence on the impact of exiting the European Union (EU) was highlighted during a House of Commons debate on 19 December 2016. This forms part of our ongoing engagement activity with MPs about pharmacology, clinical pharmacology and the EU, including our written submission to the recent inquiry by the House of Commons' Science & Technology Committee on "Leaving the EU".
On the debate topic of "Exiting the EU: Science and Research", Dr Tania Mathias MP concluded: “The Department for Exiting the European Union needs a chief scientific adviser, because it needs guidance on the metrics and on the regulations. I know that the Minister has received evidence from the British Pharmacological Society. The position in relation to the European Medicines Agency is critical. We were leading on the regulations for clinical trials, pharmacovigilance.”
In addition, Jim Shannon MP mentioned pharmacology, along with other related disciplines, in the context of the Centre for Cancer Research and Cell Biology at Queen’s University Belfast: “Opportunities for graduate and post-doctoral training are offered in partnership with several departments at the university, including: biomedical, anatomy and cell biology, biochemistry, microbiology, immunology, pharmacology and toxicology, community health and epidemiology, mathematics and statistics, oncology, pathology and medicine, and Queen’s school of policy studies.”
Read the full record of the debate proceedings and watch the footage from the House of Commons' chamber (mentions of pharmacology start at approximately 19:58:15).
